Literature DB >> 26425145

Mechanisms of immunological tolerance in central nervous system inflammatory demyelination.

Elisabeth R Mari1, Jason N Moore1, Guang-Xian Zhang1, Abdolmohamad Rostami1.   

Abstract

Multiple sclerosis is a complex autoimmune disease of the central nervous system that results in a disruption of the balance between pro-inflammatory and anti-inflammatory signals in the immune system. Given that central nervous system inflammation can be suppressed by various immunological tolerance mechanisms, immune tolerance has become a focus of research in the attempt to induce long-lasting immune suppression of pathogenic T cells. Mechanisms underlying this tolerance induction include induction of regulatory T cell populations, anergy and the induction of tolerogenic antigen-presenting cells. The intravenous administration of encephalitogenic peptides has been shown to suppress experimental autoimmune encephalomyelitis and induce tolerance by promoting the generation of regulatory T cells and inducing apoptosis of pathogenic T cells. Safe and effective methods of inducing long-lasting immune tolerance are essential for the treatment of multiple sclerosis. By exploring tolerogenic mechanisms, new strategies can be devised to strengthen the regulatory, anti-inflammatory cell populations thereby weakening the pathogenic, pro-inflammatory cell populations.

Entities:  

Keywords:  immune tolerance; interleukin-10; interleukin-27; multiple sclerosis; regulatory T cells

Year:  2015        PMID: 26425145      PMCID: PMC4584148          DOI: 10.1111/cen3.12196

Source DB:  PubMed          Journal:  Clin Exp Neuroimmunol        ISSN: 1759-1961


  130 in total

1.  Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo.

Authors:  Anette Sundstedt; Emma J O'Neill; Kirsty S Nicolson; David C Wraith
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

2.  IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

Authors:  Ivan D Mascanfroni; Ada Yeste; Silvio M Vieira; Evan J Burns; Bonny Patel; Ido Sloma; Yan Wu; Lior Mayo; Rotem Ben-Hamo; Sol Efroni; Vijay K Kuchroo; Simon C Robson; Francisco J Quintana
Journal:  Nat Immunol       Date:  2013-09-01       Impact factor: 25.606

3.  IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis.

Authors:  Yutaka Komiyama; Susumu Nakae; Taizo Matsuki; Aya Nambu; Harumichi Ishigame; Shigeru Kakuta; Katsuko Sudo; Yoichiro Iwakura
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

4.  Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation.

Authors:  Y Kuniyasu; T Takahashi; M Itoh; J Shimizu; G Toda; S Sakaguchi
Journal:  Int Immunol       Date:  2000-08       Impact factor: 4.823

5.  Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.

Authors:  Cassandra E Smith; Todd N Eagar; Jack L Strominger; Stephen D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-27       Impact factor: 11.205

6.  Augmentation of antigen-presenting and Th1-promoting functions of dendritic cells by WSX-1(IL-27R) deficiency.

Authors:  Sen Wang; Yoshiyuki Miyazaki; Yukari Shinozaki; Hiroki Yoshida
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

Review 7.  Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis.

Authors:  Danielle M Turley; Stephen D Miller
Journal:  Results Probl Cell Differ       Date:  2010

Review 8.  Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation.

Authors:  Gabriel A Rabinovich; Marta A Toscano
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

9.  Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells.

Authors:  Chiara F Magnani; Giada Alberigo; Rosa Bacchetta; Giorgia Serafini; Marco Andreani; Maria Grazia Roncarolo; Silvia Gregori
Journal:  Eur J Immunol       Date:  2011-05-13       Impact factor: 5.532

10.  A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease.

Authors:  Zoe Hunter; Derrick P McCarthy; Woon Teck Yap; Christopher T Harp; Daniel R Getts; Lonnie D Shea; Stephen D Miller
Journal:  ACS Nano       Date:  2014-02-27       Impact factor: 15.881

View more
  4 in total

1.  Peptide-Conjugated Nanoparticles Reduce Positive Co-stimulatory Expression and T Cell Activity to Induce Tolerance.

Authors:  Robert Kuo; Eiji Saito; Stephen D Miller; Lonnie D Shea
Journal:  Mol Ther       Date:  2017-04-10       Impact factor: 11.454

2.  Construction and assessment of the immunogenicity and bactericidal activity of fusion protein porin A from Neisseria meningitidis serogroups A and B admixed with OMV adjuvant as a novel vaccine candidate.

Authors:  Parviz Afrough; Mohammad Reza Asadi Karam; Farzam Vaziri; Ava Behrouzi; Seyed Davar Siadat
Journal:  Iran J Basic Med Sci       Date:  2020-06       Impact factor: 2.699

3.  Induction of Peripheral Tolerance in Ongoing Autoimmune Inflammation Requires Interleukin 27 Signaling in Dendritic Cells.

Authors:  Rodolfo Thomé; Jason N Moore; Elisabeth R Mari; Javad Rasouli; Daniel Hwang; Satoshi Yoshimura; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad M Rostami
Journal:  Front Immunol       Date:  2017-10-27       Impact factor: 7.561

4.  Interferon-γ/Interleukin-27 Axis Induces Programmed Death Ligand 1 Expression in Monocyte-Derived Dendritic Cells and Restores Immune Tolerance in Central Nervous System Autoimmunity.

Authors:  Giacomo Casella; Javad Rasouli; Rodolfo Thome; Hélène C Descamps; Asrita Vattikonda; Larissa Ishikawa; Alexandra Boehm; Daniel Hwang; Weifeng Zhang; Dan Xiao; Jeongho Park; Guang-Xian Zhang; Jorge I Alvarez; Abdolmohamad Rostami; Bogoljub Ciric
Journal:  Front Immunol       Date:  2020-10-26       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.